Miller DS - Search Results

1

Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. Krill L, et al. Among authors: miller ds. Gynecol Oncol. 2020 Feb;156(2):423-429. doi: 10.1016/j.ygyno.2019.12.003. Epub 2019 Dec 13. Gynecol Oncol. 2020. PMID: 31843273 Free PMC article.

2

The effect of naproxen on fever in patients with advanced gynecologic malignancies.

Economos K, Lucci JA 3rd, Richardson B, Yazigi R, Miller DS. Economos K, et al. Among authors: miller ds. Gynecol Oncol. 1995 Feb;56(2):250-4. doi: 10.1006/gyno.1995.1041. Gynecol Oncol. 1995. PMID: 7534741 Clinical Trial.

3

Adenovirus-based p53 gene therapy in ovarian cancer.

Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA 3rd, Miller DS, Mathis JM. Santoso JT, et al. Among authors: miller ds. Gynecol Oncol. 1995 Nov;59(2):171-8. doi: 10.1006/gyno.1995.0002. Gynecol Oncol. 1995. PMID: 7590467

4

DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.

Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR. Coleman RL, et al. Among authors: miller ds. Gynecol Oncol. 1993 Jul;50(1):20-4. doi: 10.1006/gyno.1993.1157. Gynecol Oncol. 1993. PMID: 8349159

5

In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.

von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. von Gruenigen VE, et al. Among authors: miller ds. Gynecol Oncol. 1998 Jun;69(3):197-204. doi: 10.1006/gyno.1998.5010. Gynecol Oncol. 1998. PMID: 9648587

6

Uterine metastasis from a heterologous metaplastic breast carcinoma simulating a primary uterine malignancy.

Sinkre P, Milchgrub S, Miller DS, Albores-Saavedra J, Hameed A. Sinkre P, et al. Among authors: miller ds. Gynecol Oncol. 2000 Apr;77(1):216-8. doi: 10.1006/gyno.1999.5712. Gynecol Oncol. 2000. PMID: 10739717

7

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Miller DS, et al. Am J Clin Oncol. 2000 Aug;23(4):355-7. doi: 10.1097/00000421-200008000-00009. Am J Clin Oncol. 2000. PMID: 10955863 Clinical Trial.

8

Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants.

Sherwood JB, Shivapurkar N, Lin WM, Ashfaq R, Miller DS, Gazdar AF, Muller CY. Sherwood JB, et al. Among authors: miller ds. Gynecol Oncol. 2000 Oct;79(1):90-6. doi: 10.1006/gyno.2000.5922. Gynecol Oncol. 2000. PMID: 11006038

9

Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.

Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO. Lea JS, et al. Among authors: miller ds. Gynecol Oncol. 2002 Jan;84(1):115-9. doi: 10.1006/gyno.2001.6473. Gynecol Oncol. 2002. PMID: 11748986

10

Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.

Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: miller ds. Gynecol Oncol. 2002 Feb;84(2):285-8. doi: 10.1006/gyno.2001.6524. Gynecol Oncol. 2002. PMID: 11812088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page